…Because in my opinion, that’s what a good doctor is.
As a detective, I focus on the body’s “clues” to unveil the real causes of symptoms.
I also love being a teacher, and not just when I’m standing in the lecture hall or writing articles, but also when I’m working one-on-one with clients. I take the time to explain the nature of various medical conditions, the details of the body’s brilliance and physiology, and how to best support the healing process. I believe that education is power.
Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, has patented Spravato, a filtered version of S-ketamine. But is their drug any better than the generic ketamine that’s been around since 1962? And is it worth the designer drug price tag? Dr. Zelfand explores these matters in her latest piece for Double Blind Magazine.
This webinar, hosted by Oregon Psilocybin Initiative, covers a broad range of topics, including what psilocybin is, how it works in the brain, who might potentially benefit from having access to psilocybin therapy, and the risks and safety precautions of treatment.
In this episode, Troy Farah interviews Dr. Zelfand on the off-label use of ketamine in the treatment of mood disorders, the pitfalls of many ketamine clinics, and the background story on Johnson & Johnson’s new drug, Spravato.
In this episode, Dr. Zelfand chats with Dr. Matthew Hicks about MDMA, the street drug known as “Ecstasy” or “Molly” and its clinical applications in the treatment of post-traumatic stress disorder (PTSD)
In this carefully-researched piece, Dr. Zelfand explores the off-label use of the anesthesia drug ketamine in the treatment of depression and other mood disorders.